BioSpace News Archive

Arcutis Biotherapeutics, Inc. announced that Terrie Curran has been appointed to the Arcutis Board of Directors effective Nov. 2, 2020, and that Alexander Asam, Ph.D. has decided to step down from the Board.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from the Company’s Phase 1 trial of axatilimab

Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-enabled healthcare management company, announced today its consolidated financial results for the third quarter and nine months ended September 30, 2020.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended September 30, 2020.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 26, 2020.

Innovative EVO Viva Implantable Collamer® Lens Corrects Near, Intermediate and Distance Vision

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020. “This quarter we drove strong performance through the conti

Humanigen, Inc. announced the acceptance of an abstract describing the ongoing ZUMA-19 study for presentation at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually from December 5-8, 2020.

Rare Pediatric Disease Designation received from FDA for TK216 for treatment of Ewing s arcoma Interim Phase 1 data for TK216 in 15 evaluable patients with relapsed/refractory Ewing s arcoma demonstrated two complete responses , with no relapses after complete response Strengthened the balance sheet by securing $ 10.1 million in equity financing during Q3 2020

10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.com About 10x Genomics 10x Ge